Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease

Open Forum Infectious Diseases

Volumn 2, Issue 2, 2015, Pages

  Benoit, Anne ^a   Beran, Jiri ^b   Devaster, Jeanne Marie ^c   Esen, Meral ^d   Launay, Odile ^e   Leroux Roels, Geert ^f   McElhaney, Janet E ^g   Oostvogels, Lidia ^c   van Essen, Gerrit A ^h   Gaglani, Manjusha ⁱ   Jackson, Lisa A ^j   Vesikari, Timo ^k   Legrand, Catherine ^a   Tibaldi, Fabian ^c   Innis, Bruce L ^l   Dewé, Walthère ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Vaccination and Travel Medicine Centre   (Czech Republic)

^c GSK   (Belgium)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^j GROUP HEALTH RESEARCH INSTITUTE   (United States)

^k TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

A H3N2; Influenza; Modeling; Serologic correlates; Vaccine

Indexed keywords

AS 03; BIOLOGICAL MARKER; HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC;

EID: 84978328146     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv067     Document Type: Article

References (15)

1. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77.
2. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751-9.
3. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081-5.
4. Siber GR. Methods for estimating serological correlates of protection. Dev Biol Stand 1997; 89:283-96.
5. Skowronski DM, Moser FS, Janjua NZ, et al. H3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions. PLoS One 2013; 8:e54015.
6. Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009; 200:1861-9.
7. Beran J, Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009; 9:2.
8. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010; 10:71.
9. McElhaney JE, Beran J, Devaster JM, et al. AS03-adjuvanted versus nonadjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485-96.
10. Hehme N, KünzelW, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69.
11. Tsang TK, Cauchemez S, Perera RA, et al. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis 2014; 210:684-92.
12. Kelly MJ, Dunstan FD, Lloyd K, Fone DL. Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods. BMC Psychiatry 2008; 8:10.
13. Coudeville L, Bailleux F, Riche B, et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18.
14. Dunning AJ. A model for immunological correlates of protection. Stat Med 2006; 25:1485-97.
15. Li S, Parnes M, Chan IS. Determining the cutoffbased on a continuous variable to define two populations with application to vaccines. J Biopharm Stat 2013; 23:662-80.